XML 95 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Strategic Alliances (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended 24 Months Ended
Sep. 28, 2023
Mar. 08, 2023
Sep. 14, 2021
Jul. 06, 2021
Jun. 18, 2021
May 05, 2020
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2023
Oct. 01, 2019
Revenue from Contract with Customer, Excluding Assessed Tax             $ 181,905 $ 178,595 $ 265,418 $ 237,577 $ 185,340 $ 179,744 $ 309,893 $ 329,219 $ 863,495 $ 1,004,196 $ 1,774,718    
Contract with Customer, Liability             7       138       7 138   $ 7  
Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             180,663 105,721 25,842    
CAMP4 [Member]                                      
Subsidiary, Ownership Percentage, Noncontrolling Owner       9.00%                              
Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax     $ 1,000                                
Subsidiary, Ownership Percentage, Parent     47.00%                                
Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member] | LeaderMed [Member]                                      
Payments to Acquire Interest in Joint Venture     $ 11,000                                
Subsidiary, Ownership Percentage, Noncontrolling Owner     53.00%                                
Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             1,000        
CAMP4 [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax       $ 1,500                              
Collaborative Arrangement, Upfront Payment, Shares (in shares)       3,373,008                              
Collaborative Arrangement, Period Following First Commercial Sale (Year)       10 years                              
CAMP4 [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                                 4,900    
CAMP4 [Member] | Dravet Syndrome Products [Member]                                      
Collaborative Arrangement, Development Milestone Payment       $ 3,500                              
Collaborative Arrangement, Sales Milestone Payment       $ 90,000                              
Collaborative Arrangement, Development Milestone Payment, Shares (in shares)       5,782,299                              
CAMP4 [Member] | Non-Dravet Syndrome Products [Member]                                      
Collaborative Arrangement, Development Milestone Payment       $ 4,000                              
Collaborative Arrangement, Sales Milestone Payment       $ 90,000                              
Collaborative Arrangement, Development Milestone Payment, Shares (in shares)       1,082,248                              
NICOYA Macau Limited [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                               2,500 5,000    
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                               3,000      
Pfizer Inc. [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             4,100 9,300 10,800    
BARDA Agreement [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax $ 59,000                           1,200        
Collaborative Arrangement, Development Milestone Payment $ 109,600                                    
Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount                             57,800        
Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax   $ 50,000                                  
Collaborative Arrangement, Development Milestone Payment   $ 872,500         12,500               12,500     12,500  
Collaborative Arrangement, Development Costs                             14,200        
Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             50,000        
Transfer of Intellectual Property and Other [Member] | CAMP4 [Member] | Non-Dravet Syndrome Products [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                                 $ 4,900    
Transfer of Intellectual Property and Other [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                               3,000      
Development and License Agreement [Member] | NICOYA Macau Limited [Member] | EirGen [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax         $ 5,000         2,500                  
Collaborative Arrangement, Development Milestone Payment         $ 115,000                            
Collaborative Arrangement, Period Following First Commercial Sale (Year)         10 years                            
Collaborative Agreement, Delayed Payment         $ 5,000                            
Collaborative Agreement, Delayed Payment Received, Cumulative                   $ 2,500                  
Development and License Agreement [Member] | NICOYA Macau Limited [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             2,500        
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             7,000        
Collaborative Arrangement, Sales Milestone Payment           $ 200,000                          
Collaborative Arrangement, Maximum Regulatory Milestone Payments           15,000                          
Collaborative Agreement, Option, Sales Milestone Payments           555,000                          
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | Transfer of Intellectual Property and Other [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             7,000        
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | First Marketing Approval of Rayaldee in Europe [Member] | EirGen [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax           3,000                          
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | Germany Price Approval by Local Sick Fund Association [Member] | EirGen [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax           $ 7,000                          
Pfizer Agreement [Member] | Pfizer Inc. [Member]                                      
Revenue from Contract with Customer, Excluding Assessed Tax                             90,000 85,000   175,000  
Collaborative Arrangement, Maximum Regulatory Milestone Payments                                     $ 275,000
Revenue, Remaining Performance Obligation, Amount                                     295,000
Contract with Customer, Liability             $ 0       $ 0       $ 0 $ 0   $ 0  
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Minimum [Member]                                      
Collaborative Agreements, Each Milestone Payment                                     20,000
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Maximum [Member]                                      
Collaborative Agreements, Each Milestone Payment                                     $ 90,000